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Epigenetic modification, as typified by cytosine methylation, is a key aspect of gene 
regulation that affects many biological processes. However, the biological roles of 
individual methylated cytosines are poorly understood. Sequence-specific DNA 
recognition tools can be used to investigate the roles of individual instances of DNA 
methylation. Transcription activator-like effectors (TALEs), which are DNA-binding 
proteins, are promising candidate tools with designable sequence specificity and sensitivity 
to DNA methylation. In this review, we describe the bases of DNA recognition of TALEs, 
including methylated cytosine recognition, and the applications of TALEs for the study of 
methylated DNA. In addition, we discuss TALE-based epigenome editing and oxidized 
methylated cytosine recognition. 
 





In mammals, DNA methylation occurs mainly at the fifth position of cytosine bases in CpG 
dinucleotides. The resulting 5-methylcytosine (5mC) is an important epigenetic mark that 
regulates gene expression, chromatin remodeling, and genome stability [1]. The typical 
biological change induced by 5mC is transcriptional repression due to the restricted DNA 
binding of transcription factors. Due to the importance of 5mC, many 5mC detection methods 
have been developed, including bisulfite sequencing [2] and detection with anti-5mC antibodies 
or 5mC-binding proteins [3-5]. These methods have revealed that DNA methylation status 
changes dynamically during biological events and diseases [6]. However, the biological 
functions of locus-specific 5mC are poorly understood. One strategy to explore the biological 
roles of locus-specific 5mC is the use of molecular tools that recognize 5mC in a 
sequence-specific manner in living cells. In this context, we and others have focused on 
sequence-specific DNA-binding molecules, especially transcription activator-like effectors 
(TALEs). 
DNA-binding molecules are widely used for sequence-specific gene manipulation in 
combination with various functional domains, such as transcriptional regulators, endonucleases, 
and epigenetic modifiers. For gene manipulation at desired genomic loci, DNA-binding 



































































first proteins reported with programmable sequence specificity (Fig. 1A) [7-9]. A single zinc 
finger motif recognizes 3 specific bases; its specificity is determined by the amino acid 
sequence of its α-helix [8]. By aligning specific zinc finger motifs in tandem, artificial proteins 
with desirable sequence specificity have been generated [10]. However, the DNA recognition of 
zinc finger motifs is also affected by adjacent zinc finger motifs. Satisfactory DNA binding is 
not always achieved after the modular assembly of zinc finger motifs [11, 12], which 
necessitates the laborious redesigning of zinc finger proteins. 
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 
protein 9 (Cas9) system is an impressive new tool for sequence-specific gene manipulation (Fig. 
1B) [13-15]. The CRISPR/Cas9 system recognizes a specific DNA sequence based on the 
Watson–Crick base-pairing between the 20 bases at the 5′-terminal region of the guide RNA 
(gRNA) and 1 strand of the target DNA. The Cas9 nuclease is introduced to the target region as 
a Cas9/gRNA complex, resulting in a double-strand DNA break at the target site [16]. The 
catalytically deactivated Cas9 that fuses with the functional domains enables various 
manipulations other than DNA cleavage [17, 18]. Using the CRISPR/Cas9 system, 
gene-specific manipulation can be achieved by simply designing a gRNA that is complementary 
to the target DNA. Due to its simple programmability, the CRISPR/Cas9 system has been 
rapidly adopted and widely used as a standard tool for genome manipulation.  
However, the simple DNA recognition mode of the CRISPR/Cas9 system has disadvantages for 
epigenetic research because Watson–Crick hybridization is insensitive to cytosine modifications. 
Thus, the gRNA cannot discriminate between the various epigenetic states of a target sequence. 
Furthermore, changing the DNA recognition mode of gRNA to render it sensitive to cytosine 
modification appears to be difficult. On the other hand, in most DNA–protein interactions, DNA 
recognition is mediated by the side chains of the amino acid residues of the DNA-binding 
proteins. The DNA-binding sequence specificity of proteins should be manipulable via 
modification of these interacting amino acid residues. In fact, an engineered zinc finger protein 
has shown sensitivity to methylated cytosine bases [19]. However, zinc finger proteins have 
disadvantages in terms of programmability. In contrast, TALEs are promising candidates for 
epigenetic research and therapy (Fig. 1C). TALEs have easily programmable sequence 
selectivity and sensitivity to cytosine modification. In this review, we focus on TALE 
specificity for 5mC and other modified nucleobases. In addition, we describe the applications of 




































































2. DNA-binding properties of TALE proteins 
2.1. Binding mode of TALEs 
TALEs consist of 3 domains: an N-terminal domain that harbors the type III secretion and 
translocation signal, a central repeat domain that comprises a series of tandem repeats of 
typically 34 highly conserved amino acids, and a C-terminal domain that contains nuclear 
localization signals (NLSs) and an activation domain (AD) (Fig. 2A, B) [20]. The DNA-binding 
specificities of TALEs are determined mainly by the central repeat domain. Each repeat 
recognizes 1 target base without significant effects from the neighboring repeats [21-23]. The 
base preferences of these repeats are determined by 2 amino acids, at positions 12 and 13, called 
repeat variable diresidues (RVD) (Fig. 2C). Owing to the simple recognition codes of RVD for 
DNA bases, TALEs can be readily designed to bind to desired DNA sequences. This 
programmable sequence specificity has made TALEs an attractive tool for targeted gene 
manipulation including transcriptional regulation, genome editing, live-cell imaging of specific 
chromatin loci, chromatin immunoprecipitation, and epigenetic modification (Fig. 3). 
 
2.2. DNA recognition by the central repeat domain 
More than 20 naturally occurring RVDs have been identified. Among them, NG (asparagine 
and glycine), HD (histidine and aspartic acid), NI (asparagine and isoleucine), and NN 
(asparagine and asparagine) are commonly used for the specific recognition of the nucleobases 
thymine, cytosine, adenine, and guanine/adenine, respectively [21-23]. As the RVD NN 
recognizes guanine and adenine, the RVD NH (asparagine and histidine), which is more 
guanine-specific but less active, is also used for recognition of guanine (Fig. 2A, inset) [24, 25]. 
The crystal structure of a TALE–DNA complex revealed that each repeat consists of 2 α-helixes 
with a loop between the helixes (Fig. 2C) [26, 27]. The loop region contains an RVD and 
interacts with the corresponding DNA base on the sense strand of the target DNA, thereby 
determining the specificity of the RVD. For base recognition, only the amino acid at position 13 
directly makes contact with the corresponding base, whereas the amino acid at position 12 
interacts with the amino acid at position 8 of the same repeat and stabilizes the proper loop 
conformation [26, 27]. Comprehensive analyses covering all 400 possible RVD combinations 
revealed a few novel, functional RVDs [28, 29]. These studies demonstrated the potential of 
engineered TALE repeats with desired base specificity. 
 



































































Although the central repeat domain predominantly defines TALE DNA-binding specificity, the 
N-terminal domain also contributes to TALE DNA binding. In nature, almost all TALE-binding 
sites are preceded by a conserved T nucleotide, called T0 [21, 22]. The importance of T0 for 
efficient TALE DNA binding has been experimentally demonstrated [22, 30, 31]; the presence 
of T0 restricts the sites that can be targeted by TALE-based gene manipulation. The crystal 
structures of TALEs have shown that their N-terminal domains contain 4 degenerate repeats, 
termed repeats −3, −2, −1, and 0 [26, 27, 32, 33]. Each of the 4 repeats contains 2 α-helixes 
with an adjoining loop, similar to the canonical repeats. Structural data suggested that the side 
chain of W232 in the adjoining loop of repeat −1 makes contact with T0 by van der Waals 
interactions [26]. The R266 residue in the helix of repeat −1 may also interact with T0 [33]. In 
addition, the RVD in repeat −1 reportedly affects T0 specificity [34]. Although multiple amino 
acid residues may participate in T0 recognition, several studies have shown that point mutations 
at W232 greatly modify T0 specificity [35-37]. Furthermore, the molecular evolution of the loop 
region of repeat −1 has created TALE variants that tolerate all 4 nucleotides at position zero [35, 
36]. These variants could simplify the design of the binding sites of TALE proteins. 
Furthermore, these studies demonstrated the feasibility of using directed evolution methods to 
alter the DNA recognition modes of TALE proteins. 
 
3. Recognition of cytosine methylation by TALEs 
3.1. 5mC recognition by natural RVDs 
Bultmann et al. reported that TALE-based transcriptional activation did not occur in the 
presence of 5mC in the target genomic DNA sequence [38]. In the TALE repeat that contains 
the RVD HD as a C-binder, the aspartate residue of the RVD interacts with the cytosine N4 
atom via hydrogen bond [26, 27]. Structural and biochemical analyses suggested that an 
additional methyl moiety in 5mC causes steric clash between the aspartate residue and the 
methyl moiety, resulting in a binding penalty [39, 40], which explains the silencing of the 
activity of TALEs containing the RVD HD at highly methylated target sequences.  
On the other hand, RVDs that recognize 5mC have been reported. For examples, the RVD N* 
(where * represents a deletion) tolerates 5mC [39]. This is presumably because the deletion of 
the amino acid at position 13 prevents steric clash with the additional methyl moiety of 5mC. 
The commonly used RVD NG, which is specific for thymine, has also been reported to bind 



































































enabled the application of TALE-based technology for the investigation of methylated DNA 
sequences [39, 41]. 
3.2. Discrimination of methylation states by natural and engineered RVDs 
Using RVDs that recognize 5mC, TALE-based gene manipulation can be applied to any 
sequences with cytosine methylations. In addition, using RVDs that discriminate between 
cytosine and 5mC, cytosine methylation can be assessed at the desired sequences. For example, 
the RVD HD has a stronger preference for unmodified cytosine than for 5mC [42]. Furthermore, 
new TALE scaffolds with enhanced abilities to discriminate between C and 5mC, based on 
engineered DNA backbone interactions, have been recently reported [43]. Based on the strong 
unmodified cytosine preference of the RVD HD, Kubik et al. reported sequence-specific 5mC 
detection, of even a single cytosine methylation, in oligo DNA and extracted genomic zebrafish 
DNA [42, 44].  
Although the strong preference of the RVD HD for unmodified cytosine is useful for the 
detection of cytosine methylation, an RVD with a strong 5mC preference is needed to enable 
the use of TALE-based technology to selectively manipulate methylated sites (Fig. 4). The 
RVDs NG and N* can tolerate 5mC, but their methylation discrimination abilities are not high 
[42, 45]. Therefore, to obtain new RVDs that bind to 5mC but not cytosine, bacterial 1-hybrid 
screening of a TALE repeat library was conducted [45]. In the study, a TALE repeat library was 
constructed by randomizing 4 amino acid residues, which covered RVDs and their neighboring 
residues (positions 11–14). The identified repeat having “ASAA” at positions 11-14 showed a 
strong preference for 5mC. The component amino acids, alanine and serine, are small, which 
probably minimizes steric hindrance between the RVD loop and the methyl moiety of 5mC, as 
for the RVD N*. 
 
3.3. TALE application for methylated DNA sequences 
The methylation discriminating ability of TALEs enables the use of TALE-based technology in 
a cytosine methylation-dependent manner. Specific human genomic DNA sequences have been 
isolated and 5mC has been quantitatively analyzed at single nucleotide positions using modified 
base-specific TALEs as programmable affinity probes [46]. A split protein-fused TALE system, 
which reports TALE–DNA binding as an easily detectable light signal with a low 
signal-to-background ratio[47], is another method to detect the methylation states of specific 
genomic DNA loci. In the system, a pair of TALEs fused with to the N- or C-terminal portions 



































































resulting in the reconstitution of the reporter protein activity. DNA methylation at endogenous 
genomic sites was detected using the methyl CpG binding domain of MBD1 [48] as the partner 
module of a sequence-specific TALE in a split fluorescence complementation system [49]. The 
methylation states of specific genomic DNA loci have also been detected by split luminescence 
analysis using TALEs with the ability to discriminate DNA methylation [50]. The biggest 
advantage of these systems is the ability to detect locus-specific DNA methylation in living 
cells because the split reporter-fused TALEs are genetically encodable. This live-cell 
methylation detection system is of great clinical and research value because of its sequence 
selectivity and non-invasiveness, which are improvements over previous 5mC detection 
methods. In addition to simply detecting cytosine methylation, various TALE-based gene 
manipulations, such as transcriptional activation and genome editing, have been achieved in a 
cytosine methylation-dependent manner [45, 51]. These live-cell applications provide new ways 
to explore the biological functions of modified cytosines. 
 
4. TALEs-based control of DNA methylation states at specific genomic sites 
Another approach to study the roles of individual instances of cytosine methylation is to 
manipulate the methylation states of specific genomic sites. To this end, TALEs are fused with 
methylation catalysts [52]. For example, TALEs have been fused to the catalytic domains of 
DNA methyltransferases, resulting in the successful methylation of target promoter regions [53, 
54]. The consequent silencing of the target genes demonstrated that the methylation was 
biologically functional. On the contrary, TALEs fused with the catalytic domain of ten-eleven 
translocation methylcytosine dioxygenase, which catalyzes the first step of cytosine 
demethylation, reportedly removed DNA methylation in the target region [54-56]. These 
gene-specific demethylation tools have potential for the clinical reactivation of genes, such as 
the tumor suppressor genes that are inactivated in certain cancer cells. Non-TALE DNA-binding 
molecules, including zinc finger proteins [57, 58] and gRNA/Cas9 [59-62] complexes, have 
also been used in DNA methylation and demethylation. For site-specific modulation of DNA 
methylation states, the CRISPR/Cas9 system may have a great advantage in design feasibility, 
although TALEs and zinc finger proteins have superiority abilities to distinguish between 5mC 
and C. 
 



































































Biological processes often involve active DNA demethylation, an enzymatic process that 
removes or modifies the methyl moiety from 5mC (Fig. 5). During the demethylation reaction, 
5mC is first oxidized to 5-hydroxymethylcytosine (5hmC), then to 5-formylcytosine (5fC), 
5-carboxylcytosine (5caC), and unmodified cytosine. A small number of reader proteins for 
these oxidized 5mC bases have been identified [63]. The existence of specific reader proteins 
suggests that these oxidized 5mC bases are not just intermediates during the demethylation 
process, but specific epigenetic marks with individual biological roles. Therefore, TALE 
recognition of oxidized 5mC is a matter of considerable interest. The abilities of the natural 
RVDs HD, NG, and N* to bind to cytosine, 5mC, and 5hmC were evaluated; none of the RVDs 
bound to 5hmC [64]. To obtain new RVDs with a preference for 5hmC and other oxidized 5mC 
moieties, TALE repeat mutants have been screened. Maurer et al. screened a size-reduced 
TALE repeat library, in which the TALEs had deletions of the position 13 residue to reduce the 
steric hindrance between the RVD loop and the C5 atom of modified cytosine, for binding to 
cytosine, 5mC, 5hmC, 5fC, and 5caC [65]. The repeats G*, S*, and T* showed similar affinities 
for all 5 cytosine nucleobases [65]. Zhang et al. reported a comprehensive investigation of the 
recognition ability of all 400 possible RVDs for 5hmC and 5mC and identified several RVDs 
that are specific for 5hmC [51]. Using these artificial RVDs, TALEs can be designed for 
various sequences that contain oxidized 5mC. However, RVDs with a strong preference for 
only 1 cytosine derivative have not been identified. The next goal in this field is to identify 
RVDs that bind a specific modified cytosine with high selectivity, which would enable 
modification-specific gene manipulation and greatly aid the exploration of the biological roles 
of cytosine modification. 
 
6. Conclusion 
Sequence-specific epigenome targeting has important applications in basic research and therapy. 
TALEs, which have easily programmable sequence selectivity and sensitivity to cytosine 
modification, are among the most promising molecular tools for epigenome targeting. By 
combining TALEs that can bind to modified cytosine with various functional domains, 
sequence-specific gene manipulation can be applied to genomic regions with epigenetic 
modifications. Furthermore, the discovery of TALE RVDs specific for individual cytosine 
modifications would enable the analysis of the dynamically changing epigenetic states of 
specific genomic loci in living cells. TALEs are expected to be powerful tools for epigenetic 
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Fig. 1 Schematic representation of the DNA binding of designable DNA-binding 
molecules. (A) Engineered zinc finger array, in which each module recognizes 3 bases. 
(B) In the CRISPR/Cas9 system, the gRNA/Cas9 complex recognizes target DNA 
containing the protospacer adjacent motif (PAM) sequence (red). The 5′-region (blue) 
of the gRNA undergoes Watson–Crick base-pairing with the target DNA. (C) A TALE 
contains multiple repeats (gray) that recognize a single base pair. 
 
Fig. 2 DNA binding of a TALE. (A) Schematic representation of a TALE, consisting of 
an N-terminal domain, a central repeat domain, and a C-terminal domain. The 
N-terminal domain contains 4 degenerate repeats (−3, −2, −1, and 0). The C-terminal 
domain contains NLSs and an AD. The amino acid sequence of a repeat is shown. The 
RVD and their recognized DNA bases are shown in the right box. (B) Structure of the 
DNA-binding domain of a TALE, PthXo1, bound to its target DNA sequence [PDB: 
3UGM]. (C) Structure of a repeat containing the RVD HD [PDB: 3UGM]. The RVDs 
are shown in red. 
 
Fig. 3 Applications of TALEs. (A) TALEs fused with transcriptional activators increase 
the transcription of target genes. (B) TALEs fused with transcriptional repressors 
decrease the transcription of target genes. (C) The catalytic domain of the restriction 
endonuclease FokI can be fused with TALEs to construct TALE nucleases (TALENs), 
which work as pairs. When a pair binds to adjacent target sites, the FokI domains 
dimerize and induce a double-strand DNA break at the target site. (D) TALEs fused 
with a fluorescent protein are used to visualize repetitive genomic sequences in living 
cells. (E) TALEs fused with a tag sequence are used to perform chromatin 
immunoprecipitation assays. (F) TALEs fused with epigenetic modifiers alter the 
epigenetic states of target sites.  
 
Fig. 4 Schematic of methylation-dependent gene manipulation by TALEs. TALEs with 
methylation-discriminating RVDs bind to target sites in a methylation state-dependent 





































































Fig. 5 Cytosine methylation and active demethylation.  DNMT: DNA 
methyltransferase. TET: Ten-eleven translocation dioxygenase. TDG: thymine DNA 
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